1st Quarter - Report

INFUSION PROVIDERS ALLIANCE for INFUSION PROVIDERS ALLIANCE

Firm
Client
Income
—
Expenses
$30,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

2 issue areas, each in the filer's own words, with who lobbied on it and where.

Medicare/Medicaid MMM

Implementation of provisions included in Subtitle B of PL.117-169-Inflation Reduction Act of 2022. Issues related to reimbursement of Part B drugs. Issues related to virtual supervision of infusion drugs. H.R. 879 Medicare Patient Access and Practice Stabilization Act Issues related to physician reimbursement to complex drug administration. Issues related to appropriate reimbursement for administration of Part B drugs.

LobbyistCovered position, as disclosed
BRAD TRAVERSE New Former Senior Advisor, Office of the HHS Assistant Secretary of Public Affairs

Contacted: HOUSE OF REPRESENTATIVES; SENATE; Medicare Payment Advisory Commission (MedPAC); Centers For Medicare and Medicaid Services (CMS)

Bills named: H.R. 879 (119th)

Health Issues HCR

Advocating for access to and reimbursement for biosimilars. Issues related to patient access to infusion products for asthma and allergies.

LobbyistCovered position, as disclosed
BRAD TRAVERSE —

Contacted: SENATE; HOUSE OF REPRESENTATIVES; Centers For Medicare and Medicaid Services (CMS)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.